**Table 1 References:**

[**Berwaerts J**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Berwaerts%20J%22%5BAuthor%5D)**,** [**Xu H**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xu%20H%22%5BAuthor%5D)**,** [**Nuamah I**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nuamah%20I%22%5BAuthor%5D)**,** [**Lim P**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lim%20P%22%5BAuthor%5D)**,** [**Hough D**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hough%20D%22%5BAuthor%5D) (2012). Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: randomized, double-blind, dose-response study. *Journal of Affective Disorders* **136** (1-2), 51–60.

**Bose A, Starace A, Wang Q, Diaz E, Goodman J, Ruth A, Németh G, Laszlovszky I** (2012). Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, phase III trial. ClinicalTrials.gov: NCT01058096. *European Neuropsychopharmacology* **22** (Suppl 2), S285.

**Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG** (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. *Journal of the American Medical Association* **271** (12), 918–924.

**Bowden C, Calabrese J, Ascher J, DeVeaugh-Geiss J, Earl N, Evoniuk G, Fouche N, Gibbs M, Jones D, Paska W** (2000).Spectrum of efficacy of Lamotrigine in bipolar disorder:  Overview of double-blind, placebo-controlled studies.  Study ID Number: **SCAB2009**. *American College of Neuropsychopharmacology 39th Annual Meeting*, San Juan, Puerto Rico.

**Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vågerö M, Svensson K** (2005). Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. *Journal of Clinical Psychiatry* **66** (1), 111–121.

**Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M, Depakote ER Mania Study Group** (2006). Randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. *Journal of Clinical Psychiatry* **67** (10), 1501–1510.

**Calabrese JR, Keck Jr. PE, Starace A, Lu K, Ruth A, Laszlovszky I, Nemeth G, Durgam S (2013).** Efficacy and safety of low- and high-dose cariprazine in patients with acute mania associated with bipolar I disorder. ClinicalTrials.gov: NCT01058668. *European Neuropsychopharmacology* **23** (Suppl 2), S378–S379.

[**Cutler AJ**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cutler%20AJ%22%5BAuthor%5D)**,** [**Datto C**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Datto%20C%22%5BAuthor%5D)**,** [**Nordenhem A**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nordenhem%20A%22%5BAuthor%5D)**,** [**Minkwitz M**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Minkwitz%20M%22%5BAuthor%5D)**,** [**Acevedo L**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Acevedo%20L%22%5BAuthor%5D)**,** [**Darko D**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Darko%20D%22%5BAuthor%5D) (2011). Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. [*Clinical Therapeutics*](http://www.ncbi.nlm.nih.gov/pubmed##)**33** (11), 1643–1658.

**El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R** (2010). Comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations. Study ID Number: **CN138-007**. *European Neuropsychopharmacology* **20** (11), 776–783.

**Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM** (2003). Lamotrigine: review of its use in bipolar disorder. Study ID Number: **SCAA2008**. *Drugs* **63** (19), 2029–2050.

**Hirschfeld RM, Bowden CL, Vigna NV, Wozniak P, Collins M** (2010). Randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the acute treatment of mania. ClinicalTrials.gov: NCT00060905. *Journal of Clinical Psychiatry* **71** (4), 426–432.

**Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F** (2004). Rapid antimanic effect of risperidone monotherapy: 3-week multicenter, double-blind, placebo-controlled trial. *American Journal of Psychiatry* **161** (6), 1057–1065.

**Janicak PG, Sharma RP, Pandey G, Davis JM** (1998). Verapamil for the treatment of acute mania: double-blind, placebo-controlled trial. *American Journal of Psychiatry* **155** (7), 972–973.

**Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M** (2012). Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: randomized, double-blind, placebo- and haloperidol-controlled study. *Journal of Affective Disorders* **136** (3), 476–484.

**Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G, Aripiprazole Study Group** (2003a). Placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. *American Journal of Psychiatry* **160** (9), 1651–1658.

**Keck PE Jr, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH** (2009). Aripiprazole monotherapy in the treatment of acute bipolar I mania: randomized, double-blind, placebo- and lithium-controlled study. *Journal of Affective Disorders* **112** (1-3), 36–49.

**Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K** (2003b). Ziprasidone in the treatment of acute bipolar mania: three-week, placebo-controlled, double-blind, randomized trial. *American Journal of Psychiatry* **160** (4), 741–748.

**Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M** (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. *British Journal of Psychiatry* **187**, 229–234.

**Knesevich M, Papadakis K, Bose A, Andor G, Laszlovszky I** (2009). The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.ClinicalTrials.gov: NCT00488618. *European Neuropsychopharmacology* **19** (suppl 3), S469.

**Kushner SF, Khan A, Lane R, Olson WH** (2006). Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. ClinicalTrials.gov: NCT00037674; NCT00240721; NCT00035230. *Bipolar Disorders* **8** (1), 15–27.

**McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J** (2005). Quetiapine or haloperidol as monotherapy for bipolar mania: 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. *European Neuropsychopharmacology* **15** (5), 573–585.

**McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J** (2010). Asenapine in the treatment of acute mania in bipolar I disorder: randomized, double-blind, placebo-controlled trial. *Journal of Affective Disorders* **122** (1-2), 27–38.

**McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J** (2009). Three-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disorders* **11** (7), 673–686.

**Novartis Clinical Trial Results Database** (2007). Randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and tolerability of licabazepine 1000-2000 mg/d in the treatment of manic episodes of bipolar I disorder over 3 weeks. Study ID Number: **CLIC477D2301**. ClinicalTrials.gov: NCT00099229. (Data on file).

**Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI** (1991). Valproate in the treatment of acute mania: placebo-controlled study. *Achieves of General Psychiatry* **48** (1), 62–68.

**Potkin SG, Keck PE Jr, Segal S, Ice K, English P** (2005). Ziprasidone in acute bipolar mania: 21-day randomized, double-blind, placebo-controlled replication trial. *Journal of Clinical Psychopharmacology* **25** (4), 301–310.

**Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T, Aripiprazole Study Group** (2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: 3-week placebo-controlled study. *Journal of Psychopharmacology* **20** (4), 536–546.

**Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F** (2005). Acute and continuation risperidone monotherapy in bipolar mania: 3-week placebo-controlled trial followed by 9-week double-blind trial of risperidone and haloperidol. *European Neuropsychopharmacology* **15** (1), 75–84.

**Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A** (2000). Efficacy of olanzapine in acute bipolar mania: double-blind, placebo-controlled study. *Archives of General Psychiatry* **57** (9), 841–849.

**Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V** (1999). Olanzapine vs. placebo in the treatment of acute mania. *American Journal of Psychiatry* **156** (5), 702–709.

**Tohen M, Vieta E, Goodwin G, Sun B, Amsterdam J, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu IG, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C** (2008). Olanzapine vs. divalproex vs. placebo in the treatment of mild to moderate mania: randomized, 12-week, double-blind study. *Journal of Clinical Psychiatry* **69** (11), 1776–1789.

**Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J** (2010a). Randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. ClinicalTrials.gov: NCT00309699. *Bipolar Disorders* **12** (3), 230–243.

**Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J** (2010b). Ziprasidone in the treatment of acute mania: 12-week placebo-controlled, haloperidol-referenced study. *Journal of Psychopharmacology* **24** (4), 547–558.

**Weisler RH, Kalali AH, Ketter TA** (2004). Multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. *Journal of Clinical Psychiatry* **65** (4), 478–484.

**Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH** (2005). Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: multicenter, randomized, double-blind, placebo-controlled trial. *Journal of Clinical Psychiatry* **66** (3), 323–330.

**Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF** (2008). Protein kinase C inhibition in the treatment of mania: double-blind, placebo-controlled trial of tamoxifen. *Archives of General Psychiatry* **65** (3), 255–263.

**Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, Spiller NH, Torbeyns AF, Sanchez R** (2009). Aripiprazole monotherapy in acute mania: 12-week, randomized placebo- and haloperidol-controlled study. *British Journal of Psychiatry* **194** (1), 40–48.

**Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK** (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. *Bipolar Disorders* **9** (6), 561–570.

**Table 2 References: Duplicate reference from placebo controlled three-arm studies are in blue.**

**Berk M, Ichim L, Brook S** (1999). Olanzapine compared to lithium in mania: double-blind randomized controlled trial. *International Journal of Clinical Psychopharmacology* **14** (6), 339–343.

**Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG** (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. *Journal of the American Medical Association* **271** (12), 918–924.

**Bowden C, Calabrese J, Ascher J, DeVeaugh-Geiss J, Earl N, Evoniuk G, Fouche N, Gibbs M, Jones D, Paska W** (2000).Spectrum of efficacy of Lamotrigine in bipolar disorder:  Overview of double-blind, placebo-controlled studies.  Study ID Number: **SCAB2009**. *American College of Neuropsychopharmacology 39th Annual Meeting*, San Juan, Puerto Rico.

**Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vågerö M, Svensson K** (2005). Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. *Journal of Clinical Psychiatry* **66** (1), 111–121.

**Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC** (1992). Double-blind comparison of valproate and lithium in the treatment of acute mania. *American Journal of Psychiatry* **149** (1), 108–111.

**Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM** (2003). Lamotrigine: review of its use in bipolar disorder. Study ID Number: **SCAA2008**. *Drugs* **63** (19), 2029–2050.

**Ichim L, Berk M, Brook S** (2000). Lamotrigine compared with lithium in mania: double-blind randomized controlled trial. *Annals of Clinical Psychiatry* **12** (1), 5–10.

**Kakkar AK, Rehan HS, Unni KES, Gupta NK, Chopra D, Kataria D** (2009). Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: pilot study. *European Psychiatry* **24** (3), 178–182.

**Li H, Ma C, Wang G, Zhu X, Peng M, Gu N** (2008). Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: randomized and double-blind study. ClinicalTrials.gov: NCT00448578. *Current Medical Research and Opinion* **24** (1), 1–10.

**Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M** (2012). Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: randomized, double-blind, placebo- and haloperidol-controlled study. *Journal of Affective Disorders* **136** (3), 476–484.

**Keck PE Jr, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH** (2009). Aripiprazole monotherapy in the treatment of acute bipolar I mania: randomized, double-blind, placebo- and lithium-controlled study. *Journal of Affective Disorders* **112** (1-3), 36–49.

**Kushner SF, Khan A, Lane R, Olson WH** (2006). Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. ClinicalTrials.gov: NCT00037674; NCT00240721; NCT00035230. *Bipolar Disorders* **8** (1), 15–27.

**McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM** (1996). Randomized comparison of divalproex oral loading vs. haloperidol in the initial treatment of acute psychotic mania. *Journal of Clinical Psychiatry* **57** (4), 142–146.

**McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J** (2005). Quetiapine or haloperidol as monotherapy for bipolar mania: 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. *European Neuropsychopharmacology* **15** (5), 573–585.

**McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J** (2010). Asenapine in the treatment of acute mania in bipolar I disorder: randomized, double-blind, placebo-controlled trial. *Journal of Affective Disorders* **122** (1-2), 27–38.

**McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J** (2009). Three-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disorders* **11** (7), 673–686.

**Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S** (2008). Olanzapine vs. lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. ClinicalTrials.gov: NCT00485680. *Journal of Affective Disorders* **105** (1-3), 101–108.

**Perlis RH, Baker RW, Zarate CA Jr, Brown EB, Schuh LM, Jamal HH, Tohen M** (2006). Olanzapine vs. risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. *Journal of Clinical Psychiatry* **67** (11), 1747–1753.

**Segal J, Berk M, Brook S** (1998). Risperidone compared with both lithium and haloperidol in mania: double-blind randomized controlled trial. *Clinical Neuropharmacology* **21** (3), 176–180.

**Shafti SS** (2010). [Olanzapine vs. lithium in management of acute mania.](http://www.ncbi.nlm.nih.gov/pubmed/19740546) *Journal of Affective Disorders* **122** (3), 273–276.

**Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF** (1991). Carbamazepine compared with lithium in the treatment of mania. *Achieves of General Psychiatry* **48** (10), 915–921.

**Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F** (2005). Acute and continuation risperidone monotherapy in bipolar mania: 3-week placebo-controlled trial followed by 9-week double-blind trial of risperidone and haloperidol. *European Neuropsychopharmacology* **15** (1), 75–84.

**Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA** (2002). Olanzapine vs. divalproex in the treatment of acute mania. *American Journal of Psychiatry* **159** (6), 1011–1017.

**Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A** (2003). 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. *Archives of General Psychiatry* **60** (12), 1218–1226.

**Tohen M, Vieta E, Goodwin G, Sun B, Amsterdam J, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu IG, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C** (2008). Olanzapine vs. divalproex vs. placebo in the treatment of mild to moderate mania: randomized, 12-week, double-blind study. *Journal of Clinical Psychiatry* **69** (11), 1776–1789.

**Vasudev K, Goswami U, Kohli K** (2000). [Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder.](http://www.ncbi.nlm.nih.gov/pubmed/10867972) *Psychopharmacology* **150** (1), 15–23.

**Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T** (2005). Effectiveness of aripiprazole vs. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. *British Journal of Psychiatry* **187**, 235–242.

**Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J** (2010a). Randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. ClinicalTrials.gov: NCT00309699. *Bipolar Disorders* **12** (3), 230–243.

**Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J** (2010b). Ziprasidone in the treatment of acute mania: 12-week placebo-controlled, haloperidol-referenced study. *Journal of Psychopharmacology* **24** (4), 547–558.

**Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, Spiller NH, Torbeyns AF, Sanchez R** (2009). Aripiprazole monotherapy in acute mania: 12-week, randomized placebo- and haloperidol-controlled study. *British Journal of Psychiatry* **194** (1), 40–48.

**Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW** (2002). Comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. *Journal of Clinical Psychiatry* **63** (12), 1148–1155.